Shengui Sansheng San alleviates the worsening of blood–brain barrier integrity resulted from delayed tPA administration through VIP/VIPR1 pathway

Shengui Sansheng San alleviates the worsening of blood–brain barrier integrity resulted from delayed tPA administration through VIP/VIPR1 pathway

Abstract Background Intravenous tissue plasminogen activator (tPA) is currently the only FDA-approved thrombolytic therapy for acute ischemic stroke (AIS), however, relative narrow therapeutic time window (within 4.5 h of AIS onset) and high risk of hemorrhagic transformation due to blood–brain barr...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiacheng Hu, Yiyang Li, Xingping Quan, Yan Han, Jinfen Chen, Mengchen Yuan, Ying Chen, Manfei Zhou, Enze Yu, Jiahao Zhou, Dawei Wang, Ruibing Wang, Yonghua Zhao
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Chinese Medicine
Subjects:
Acute ischemic stroke
Blood brain barrier
Shengui Sansheng San
Tissue plasminogen activator
VIP/VIPR1
Online Access:https://doi.org/10.1186/s13020-025-01079-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13020-025-01079-0

Similar Items